Skip to main content
UniHealth

Doctor search

Judy J Chen, MD

Ophthalmology · San Francisco

NPI 1265875611

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Office
1
Since medical school
14 years
University of Chicago, Pritzker School of Medicine, 2012

Offices

1 location · West Coast Retina Medical Group Inc · 8 clinicians in this group

Looking this up.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chen’s office at (415) 972-4600 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

California Medical Board record

Licence A141948 · Current

Licensed to practise in California · since 2016 · expires 2027-08-31 · University of Chicago, Pritzker School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Ophthalmology - Ophthalmology

Original Medicare doctor bills

$2,872,699

Medicare paid this office $2,872,699 for 1,079 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Injection, aflibercept, 1 mg250$1,438,078None
Injection, faricimab-svoa, 0.1 mg102$714,087None
Injection of drug into eye404$191,907$126
Injection, ranibizumab, 0.1 mg42$123,096None
Established patient complete exam of visual system695$114,891$120
See all 13 services
Every Original Medicare service billed
Injection, aflibercept, 1 mg250$1,438,078None
Injection, faricimab-svoa, 0.1 mg102$714,087None
Injection of drug into eye404$191,907$126
Injection, ranibizumab, 0.1 mg42$123,096None
Established patient complete exam of visual system695$114,891$120
Imaging of retina1,061$100,184$40
Injection, aflibercept hd, 1 mg11$82,382None
New patient complete exam of visual system120$16,877$141
Compounded drug, not otherwise classified51$11,406None
Exam of retinal blood vessels using a special camera after injection of a dye15$2,759$184
Photography of the retina53$1,960$34
Established patient problem focused exam of visual system11$1,364$80
2d ultrasound scan of eye tissue and structures12$1,293$50

Procedures Medicare counted

Procedure volume Medicare published
Cataract surgery1-10None

Procedures year by year

Procedures billed to Original Medicare by year
Procedure201920202021202220232024
Injection of drug into eye1,7491,2661,5071,1501,4121,529

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

1,079 Original Medicare patients in 2024. Average age 80 · Under 65 2% · 85 and older 29% · Women 60% · Also on Medicaid 13% · Health risk score 1.34. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.

Conditions among them: High blood pressure 73% · Diabetes 25% · Chronic kidney disease 25% · Coronary heart disease 22% · Atrial fibrillation 18% · Cancer 16% · Depression 16% · Heart failure 13% · COPD 10% · Stroke 8% · Dementia 7%.

The office billed $17,800,210, Medicare allowed $3,648,256 and paid $2,872,699; for 35,398 services of 40 kinds; $2,375,580 of it was for drugs given in the office and $497,119 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20241,07935,398801.34$17,800,210$2,872,699
202396223,621791.22$12,914,095$2,303,092
202291410,137791.25$9,326,140$1,671,466
20211,0078,846791.24$10,872,730$1,992,189
20207286,801801.34$7,271,470$1,318,474
20191,05310,384791.37$7,138,878$1,743,495
20188695,922791.34$3,206,779$951,150
2017101374761.53$264,638$80,470
201634103760.92$69,938$23,331

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 12 services

Original Medicare services billed in 2023
Injection, aflibercept, 1 mg221$1,223,401None
Injection, faricimab-svoa, 0.1 mg70$457,515None
Injection, ranibizumab, 0.1 mg50$190,568None
Injection of drug into eye365$163,050$115
Imaging of retina947$83,277$37
Established patient complete exam of visual system564$82,036$111
Compounded drug, not otherwise classified98$24,583None
New patient complete exam of visual system136$18,088$133
Established patient problem focused exam of visual system25$2,417$83
Exam of retinal blood vessels using a special camera after injection of a dye11$1,610$146
Photography of the retina32$1,125$34
2d ultrasound scan of eye tissue and structures11$883$46

2022: 12 services

Original Medicare services billed in 2022
Injection, aflibercept, 1 mg170$996,604None
Injection, ranibizumab, 0.1 mg46$180,420None
Injection of drug into eye320$126,411$110
Injection, faricimab-svoa, 0.1 mg30$91,314None
Established patient complete exam of visual system548$78,394$108
Imaging of retina874$69,079$36
Unclassified drugs16$43,698None
Compounded drug, not otherwise classified135$32,764None
New patient complete exam of visual system126$16,065$127
Exam of retinal blood vessels using a special camera after injection of a dye25$3,218$129
Established patient problem focused exam of visual system28$2,922$75
Photography of the retina59$1,958$33

2021: 12 services

Original Medicare services billed in 2021
Injection, aflibercept, 1 mg129$1,256,093None
Injection, ranibizumab, 0.1 mg38$223,471None
Injection of drug into eye315$175,421$116
Imaging of retina953$90,281$37
Established patient complete exam of visual system542$84,541$113
Compounded drug, not otherwise classified170$61,631None
New patient complete exam of visual system213$29,037$136
Exam of retinal blood vessels using a special camera after injection of a dye55$6,740$123
Return visit (30+ min)82$5,185$62
Photography of the retina100$4,179$36
New patient visit (45+ min)22$2,200$100
2d ultrasound scan of eye tissue and structures15$880$49

2020: 10 services

Original Medicare services billed in 2020
Injection, aflibercept, 1 mg101$759,324None
Injection, ranibizumab, 0.1 mg39$210,103None
Injection of drug into eye319$120,442$95
Compounded drug, not otherwise classified199$63,774None
Imaging of retina694$60,505$34
Established patient complete exam of visual system387$50,264$101
New patient complete exam of visual system98$11,797$120
Exam of retinal blood vessels using a special camera after injection of a dye29$3,078$106
Photography of the retina48$1,967$40
Established patient problem focused exam of visual system11$1,056$81

2019: 11 services

Original Medicare services billed in 2019
Injection, aflibercept, 1 mg98$761,400None
Injection, ranibizumab, 0.1 mg107$438,608None
Injection of drug into eye366$173,134$99
Imaging of retina989$97,536$37
Established patient complete exam of visual system615$91,569$108
Compounded drug, not otherwise classified257$85,965None
New patient complete exam of visual system189$24,229$128
Exam of retinal blood vessels using a special camera after injection of a dye58$5,238$90
Photography of the retina72$3,433$45
Established patient problem focused exam of visual system18$1,391$77
2d ultrasound scan of eye tissue and structures16$1,319$60

2018: 11 services

Original Medicare services billed in 2018
Injection, aflibercept, 1 mg72$356,792None
Injection, ranibizumab, 0.1 mg60$232,618None
Injection of drug into eye340$102,271$102
Established patient complete exam of visual system441$65,492$114
Imaging of retina760$60,631$39
Compounded drug, not otherwise classified230$48,824None
New patient complete exam of visual system210$28,345$135
Exam of retinal blood vessels using a special camera after injection of a dye65$5,739$84
Photography of the retina95$5,242$52
Removal of eye fluid12$1,020$85
2d ultrasound scan of eye tissue and structures11$898$75

2017: 6 services

Original Medicare services billed in 2017
Injection, aflibercept, 1 mg18$32,097None
Injection, ranibizumab, 0.1 mg17$28,180None
Injection of drug into eye48$4,935$101
Established patient complete exam of visual system28$3,285$117
Imaging of retina61$2,339$38
Short return visit (20+ min)15$1,024$60

2016: 3 services

Original Medicare services billed in 2016
Established patient complete exam of visual system19$2,434$122
Injection of drug into eye13$1,361$105
Imaging of retina14$625$45

Medicaid work

$214,248 in 2024

Medicaid paid $214,248 for 1,008 billed services this clinician did in 2024, up to 58 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Intravitreal injection of a pharmacologic agent (separate procedure)327$102,885
Aflibercept injection68$85,470
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina477$16,773
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST123$8,186
OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST13$934
Medicaid work by year
20241,008558$214,248
20231,413758$309,100
2022969756$103,916
20211,1341050$87,806
2020678454$48,853
2019832445$53,865
2018198327$12,903
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Intravitreal injection of a pharmacologic agent (separate procedure)468$192,935
Aflibercept injection50$72,287
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina615$24,416
Injection, bevacizumab, 10 mg114$8,545
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST120$8,065
OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST28$1,837
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient18$1,015

2022

Largest Medicaid services in 2022
Intravitreal injection of a pharmacologic agent (separate procedure)267$67,471
Aflibercept injection36$18,881
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina411$11,165
Injection, bevacizumab, 10 mg52$2,381
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST64$2,348
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient36$1,664
Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease103$7

2021

Largest Medicaid services in 2021
Intravitreal injection of a pharmacologic agent (separate procedure)343$61,857
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina513$14,123
Aflibercept injection15$4,032
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST75$2,496
Injection, bevacizumab, 10 mg32$1,706
Return visit (30+ min)33$1,538
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient25$1,394
OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST12$508
Compounded drug, not otherwise classified14$140
Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease72$11

2020

Largest Medicaid services in 2020
Intravitreal injection of a pharmacologic agent (separate procedure)250$38,516
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina347$8,763
Compounded drug, not otherwise classified53$837
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST28$736

2019

Largest Medicaid services in 2019
Intravitreal injection of a pharmacologic agent (separate procedure)284$44,656
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina437$7,089
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST50$1,835
Compounded drug, not otherwise classified61$285

2018

Largest Medicaid services in 2018
Clinic visit/encounter, all-inclusive28$6,529
Intravitreal injection of a pharmacologic agent (separate procedure)41$4,086
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina129$2,289

Drugs they prescribed that Part D paid

$21,261

Pharmacies billed $21,261 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 304) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.

191 generic and 113 brand-name prescriptions · $21,261 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Prolensa11$3,726$339
Prednisolone Acetate61$3,525$58
Bromfenac18$2,717$151
Ketorolac Tromethamine21$411$20
Dorzolamide-Timolol22$269$12
See all 10 drugs
Every Part D drug this clinician prescribed
Prolensa11$3,726$339
Prednisolone Acetate61$3,525$58
Bromfenac18$2,717$151
Ketorolac Tromethamine21$411$20
Dorzolamide-Timolol22$269$12
Brimonidine25$227$9
Polymyxin B Sul-Trimethoprim27$215$8
Latanoprost23$158$7
Azelastine21$155$7
Timolol Maleate11$64$6

Year by year

Part D prescribing by year
2024304970% (0)37%$21,261
2023309119None41%$27,751
202221992None46%$22,993
20213021110% (0)54%$27,128
202019496None47%$14,025
2019266107None44%$19,646
201822885NoneNone$21,576
201724872None46%$22,053
20167001800% (0)35%$51,408
2015676185None48%$66,578
2014229700% (0)52%$37,737
201376310% (0)39%$4,947

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 11 drugs

Part D drugs prescribed in 2023
Prolensa20$8,006$400
Prednisolone Acetate70$5,333$76
Difluprednate15$2,195$146
Bromfenac12$1,944$162
Moxifloxacin18$587$33
Dorzolamide-Timolol23$529$23
Latanoprost15$251$17
Olopatadine13$235$18
Neomycin-Polymyxin-Dexameth11$205$19
Polymyxin B Sul-Trimethoprim21$190$9
Brimonidine12$161$13

2022: 6 drugs

Part D drugs prescribed in 2022
Prednisolone Acetate52$3,837$74
Timolol Maleate13$1,338$103
Azelastine11$427$39
Latanoprost13$278$21
Dorzolamide-Timolol11$197$18
Polymyxin B Sul-Trimethoprim16$140$9

2021: 9 drugs

Part D drugs prescribed in 2021
Prolensa33$10,729$325
Prednisolone Acetate72$5,127$71
Olopatadine11$601$55
Latanoprost20$455$23
Azelastine17$421$25
Polymyxin B Sul-Trimethoprim30$251$8
Neomycin-Polymyxin-Dexameth19$248$13
Brimonidine16$214$13
Timolol Maleate14$105$8

2020: 6 drugs

Part D drugs prescribed in 2020
Prednisolone Acetate29$2,282$79
Olopatadine20$1,114$56
Azelastine18$255$14
Brimonidine11$192$17
Erythromycin12$150$12
Polymyxin B Sul-Trimethoprim16$128$8

2019: 9 drugs

Part D drugs prescribed in 2019
Prednisolone Acetate58$4,099$71
Prolensa13$3,599$277
Olopatadine22$1,838$84
Brimonidine17$413$24
Polymyxin B Sul-Trimethoprim32$287$9
Neomycin-Polymyxin-Dexameth17$253$15
Ketorolac Tromethamine14$208$15
Timolol Maleate15$176$12
Erythromycin15$161$11

2018: 5 drugs

Part D drugs prescribed in 2018
Prednisolone Acetate44$2,729$62
Dorzolamide-Timolol13$346$27
Brimonidine20$321$16
Polymyxin B Sul-Trimethoprim17$158$9
Timolol Maleate16$118$7

2017: 7 drugs

Part D drugs prescribed in 2017
Travatan Z26$6,432$247
Alphagan P20$4,196$210
Zioptan11$2,039$185
Dorzolamide-Timolol32$919$29
Latanoprost35$540$15
Brimonidine20$238$12
Timolol Maleate19$122$6

2016: 15 drugs

Part D drugs prescribed in 2016
Travatan Z40$9,382$235
Combigan23$5,267$229
Prednisolone Acetate46$3,664$80
Lumigan12$2,396$200
Brimonidine66$2,051$31
Latanoprost151$1,968$13
Pataday12$1,924$160
Dorzolamide-Timolol94$1,718$18
Pilocarpine20$830$42
Doxycycline Hyclate15$737$49
Ketorolac Tromethamine27$546$20
Dorzolamide23$379$16
Erythromycin34$304$9
Timolol Maleate31$271$9
Polymyxin B Sul-Trimethoprim13$120$9

2015: 14 drugs

Part D drugs prescribed in 2015
Travatan Z57$11,199$196
Restasis15$8,698$580
Azopt21$5,568$265
Combigan24$4,653$194
Alphagan P24$4,637$193
Pataday14$4,604$329
Brimonidine59$2,766$47
Prednisolone Acetate50$2,626$53
Dorzolamide-Timolol65$2,008$31
Latanoprost102$1,670$16
Timolol Maleate45$1,362$30
Pilocarpine17$1,064$63
Dorzolamide37$676$18
Erythromycin35$444$13

2014: 8 drugs

Part D drugs prescribed in 2014
Travatan Z19$3,669$193
Pataday19$3,073$162
Lumigan11$2,817$256
Brimonidine25$1,367$55
Prednisolone Acetate16$1,004$63
Latanoprost45$648$14
Dorzolamide-Timolol25$514$21
Erythromycin14$218$16

Money from drug and device companies

$7,758 in 2025

Industry payments by year
2025825$6,325$7,758
2024516$2,640$3,500
2023512None$507
2022411None$760
202125$1,980$2,071
202024None$92
201949None$374

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Genentech USAVabysmo$6,411
9 payments
  • Meals for Vabysmo · 2025-12-09 · $35
  • Meals for Vabysmo · 2025-09-16 · $33
  • Meals for Vabysmo · 2025-07-29 · $25
  • Travel for Vabysmo · 2025-07-29 · $126
  • Consulting for Vabysmo · 2025-07-29 · $5,595
  • Meals for Vabysmo · 2025-07-29 · $213
  • Travel for Vabysmo · 2025-07-29 · $320
  • Meals for Vabysmo · 2025-04-15 · $29
  • Meals for Vabysmo · 2025-01-28 · $35
GenentechSusvimo$730
1 payment
  • Consulting for Susvimo · 2025-12-15 · $730
Alcon VisionHydrus Microstent$229
2 payments
  • Meals for Hydrus Microstent · 2025-10-22 · $90
  • Meals for Hydrus Microstent · 2025-02-28 · $140
ANI PharmaceuticalsYutiq$170
6 payments
  • Meals for Iluvien · 2025-11-18 · $32
  • Meals for Iluvien · 2025-09-23 · $23
  • Meals for Yutiq · 2025-07-08 · $20
  • Meals for Yutiq · 2025-05-10 · $33
  • Meals for Yutiq · 2025-03-11 · $31
  • Meals for Purified Cortrophin Gel · 2025-01-14 · $31
Regeneron Healthcare SolutionsEylea Hd$122
4 payments
  • Meals for Eylea Hd · 2025-12-16 · $32
  • Meals for Eylea Hd · 2025-08-26 · $32
  • Meals for Eylea Hd · 2025-04-29 · $26
  • Meals for Eylea Hd · 2025-02-04 · $32
Johnson & Johnson Surgical VisionTecnis Iol$38
1 payment
  • Meals for Tecnis Iol · 2025-04-09 · $38
See all 25 published payments
Every published payment
Regeneron Healthcare SolutionsMeals · 2025-12-16Eylea Hd$32
GenentechConsulting · 2025-12-15Susvimo$730
Genentech USAMeals · 2025-12-09Vabysmo$35
ANI PharmaceuticalsMeals · 2025-11-18Iluvien$32
Alcon VisionMeals · 2025-10-22Hydrus Microstent$90
ANI PharmaceuticalsMeals · 2025-09-23Iluvien$23
Genentech USAMeals · 2025-09-16Vabysmo$33
Regeneron Healthcare SolutionsMeals · 2025-08-26Eylea Hd$32
Astellas Pharma USMeals · 2025-08-19Izervay$30
Genentech USAMeals · 2025-07-29Vabysmo$25
Genentech USATravel · 2025-07-29Vabysmo$126
Genentech USAConsulting · 2025-07-29Vabysmo$5,595
Genentech USAMeals · 2025-07-29Vabysmo$213
Genentech USATravel · 2025-07-29Vabysmo$320
ANI PharmaceuticalsMeals · 2025-07-08Yutiq$20
ANI PharmaceuticalsMeals · 2025-05-10Yutiq$33
Regeneron Healthcare SolutionsMeals · 2025-04-29Eylea Hd$26
Genentech USAMeals · 2025-04-15Vabysmo$29
Johnson & Johnson Surgical VisionMeals · 2025-04-09Tecnis Iol$38
ANI PharmaceuticalsMeals · 2025-03-11Yutiq$31
Alcon VisionMeals · 2025-02-28Hydrus Microstent$140
Regeneron Healthcare SolutionsMeals · 2025-02-04Eylea Hd$32
Genentech USAMeals · 2025-01-28Vabysmo$35
ANI PharmaceuticalsMeals · 2025-01-14Purified Cortrophin Gel$31
AbbvieMeals · 2025-01-09Ozurdex$28
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $3,500

Payments by company in 2024
Genentech USASusvimo$3,332
10 payments
  • Meals for Susvimo · 2024-11-18 · $23
  • Meals for Vabysmo · 2024-11-12 · $35
  • Meals for Susvimo · 2024-08-19 · $30
  • Meals for Susvimo · 2024-07-17 · $68
  • Travel for Susvimo · 2024-07-16 · $169
  • Consulting for Susvimo · 2024-07-16 · $2,640
  • Meals for Susvimo · 2024-07-16 · $50
  • Meals for Susvimo · 2024-07-16 · $69
  • Travel for Susvimo · 2024-07-16 · $219
  • Meals for Vabysmo · 2024-06-19 · $30
Regeneron Healthcare SolutionsEylea Hd$91
3 payments
  • Meals for Eylea Hd · 2024-10-29 · $33
  • Meals for Eylea Hd · 2024-05-30 · $33
  • Meals for Eylea Hd · 2024-02-01 · $25
Bausch & Lomb AmericasXipere$31
1 payment
  • Meals for Xipere · 2024-02-28 · $31
Carl Zeiss Meditec USANone$30
1 payment
  • Meals · 2024-10-12 · $30
Regeneron PharmaceuticalsEylea Hd$16
1 payment
  • Meals for Eylea Hd · 2024-06-19 · $16

2023: $507

Payments by company in 2023
Alcon VisionHydrus Microstent$145
3 payments
  • Meals for Hydrus Microstent · 2023-12-08 · $102
  • Meals for Hydrus Microstent · 2023-11-10 · $22
  • Meals for Clareon · 2023-10-05 · $22
Genentech USAVabysmo$139
5 payments
  • Meals for Vabysmo · 2023-10-09 · $20
  • Meals for Vabysmo · 2023-09-12 · $32
  • Meals · 2023-05-02 · $34
  • Meals for Vabysmo · 2023-04-04 · $18
  • Meals for Vabysmo · 2023-02-14 · $35
Bausch & Lomb AmericasXipere$131
1 payment
  • Meals for Xipere · 2023-03-21 · $131
Regeneron Healthcare SolutionsEylea Hd$61
2 payments
  • Meals for Eylea Hd · 2023-09-05 · $34
  • Meals for Eylea · 2023-05-09 · $27
AbbVieDurysta$30
1 payment
  • Meals for Durysta · 2023-05-17 · $30

2022: $760

Payments by company in 2022
Alcon VisionHydrus Microstent$498
4 payments
  • Meals for Clareon · 2022-12-09 · $71
  • Meals for Clareon · 2022-11-17 · $80
  • Meals for Hydrus Microstent · 2022-09-09 · $201
  • Meals for Acrysof Iq Panoptix Uv Iol · 2022-05-14 · $146
AbbvieXen Glaucoma Treatment System$139
2 payments
  • Meals for Xen Glaucoma Treatment System · 2022-11-16 · $109
  • Meals for Ozurdex · 2022-07-11 · $29
Genentech USAVabysmo$105
4 payments
  • Meals for Vabysmo · 2022-11-16 · $31
  • Meals for Vabysmo · 2022-09-01 · $33
  • Meals for Vabysmo · 2022-07-27 · $19
  • Meals for Susvimo · 2022-02-22 · $22
Regeneron Healthcare SolutionsEylea$18
1 payment
  • Meals for Eylea · 2022-02-03 · $18

2021: $2,071

Payments by company in 2021
Genentech USALucentis$2,045
4 payments
  • Meals for Susvimo · 2021-10-26 · $25
  • Consulting for Lucentis · 2021-10-16 · $1,980
  • Meals for Lucentis · 2021-05-05 · $15
  • Meals for Lucentis · 2021-03-04 · $25
Regeneron Healthcare SolutionsEylea$26
1 payment
  • Meals for Eylea · 2021-10-19 · $26

2020: $92

Payments by company in 2020
Genentech USALucentis$74
3 payments
  • Meals for Lucentis · 2020-12-21 · $25
  • Meals for Lucentis · 2020-05-05 · $25
  • Meals for Lucentis · 2020-03-11 · $24
GenentechLucentis$17
1 payment
  • Meals for Lucentis · 2020-01-22 · $17

2019: $374

Payments by company in 2019
GenentechLucentis$213
3 payments
  • Meals for Lucentis · 2019-10-12 · $43
  • Meals for Non-Covered Product · 2019-10-11 · $59
  • Meals for Lucentis · 2019-03-21 · $111
Carl Zeiss MeditecNone$70
1 payment
  • Meals · 2019-05-31 · $70
Novartis PharmaceuticalsDurezol$60
3 payments
  • Meals for Beovu · 2019-11-08 · $16
  • Meals · 2019-06-11 · $16
  • Meals for Durezol · 2019-01-26 · $28
Genentech USALucentis$31
2 payments
  • Meals for Lucentis · 2019-08-29 · $14
  • Meals for Lucentis · 2019-06-26 · $17

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Genentech, Inc. · Va2 Phiii Yosemite · 2020Their institution$158,108
Genentech, Inc. · Va2 Phiii Yosemite · 2019Their institution$109,157
Genentech, Inc. · Va2 Phiii Yosemite · 2021Their institution$105,528
Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2019Their institution$92,477
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2022Their institution$84,698
Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2020Their institution$77,856
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2021Their institution$57,963
Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2020Their institution$42,767
Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2021Their institution$30,871
Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2022Their institution$21,573
Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2023Their institution$21,088
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2023Their institution$14,838
Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2019Their institution$12,444
Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2021Their institution$10,782
Boehringer Ingelheim International GmbH · A Randomized, Double-Masked, Placebo-Controlled Trial To Evaluate the Efficacy, Safety and Tolerability of Oral Bi1815368 in Participants With Center-Involved Diabetic Macular Edema · 2025Their institution$889

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
70.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1265875611
Licence
CA A141948California A141948: Current · expires 2027-08-31
Trained
University of Chicago, Pritzker School of Medicine, 2012 · 14 years ago
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X)
Mailing address
1445 Bush St, San Francisco, CA, 94109
NPI first listed
2013-04-15
NPI last updated
2020-08-21
NPI record certified
2020-08-21

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 100 Tamal Plz Ste 120, Corte Madera, CA, 94925 · 400 30th St Ste 402, Oakland, CA, 94609 · 101 S San Mateo Dr Ste 306, San Mateo, CA, 94401 · 1981 N Broadway Ste 265, Walnut Creek, CA, 94596

This office lists an electronic records connection.